Management of Heart Failure with Reduced Ejection Fraction (HFrEF) using Beta-Blockers
Guideline Recommendations
- The American Heart Association, American College of Cardiology, and Heart Failure Society of America recommend using one of three beta-blockers proven to reduce mortality in HFrEF: bisoprolol, carvedilol, or sustained-release metoprolol succinate 1, 2, 3
- These beta-blockers have a Class I, Level of Evidence A recommendation for all patients with current or previous symptoms of HFrEF 1, 2
- Beta-blocker therapy provides high economic value in HFrEF management 1
- Guidelines do not express a preference between carvedilol and metoprolol succinate, considering them equally effective based on major clinical trials 1, 3
Dosing Considerations
- Target doses for beta-blockers in HFrEF are:
- Guidelines recommend titrating to target doses or maximally tolerated doses 4, 5
- At least 50% of target dose should be achieved when possible 4, 5
Clinical Approach to Selection
- The American College of Cardiology recommends considering patient-specific factors when selecting between carvedilol and metoprolol succinate 3
- The American College of Cardiology suggests starting at low doses and titrating gradually to target doses 1
- The American College of Cardiology recommends maintaining long-term treatment even if symptoms improve 1
Common Pitfalls to Avoid
- Abrupt discontinuation of either beta-blocker can lead to clinical deterioration and should be avoided 1
- Using non-evidence-based beta-blockers (other than carvedilol, metoprolol succinate, or bisoprolol) is not recommended 1
- Failure to titrate to target doses may result in suboptimal outcomes 4, 5
- Not recognizing that beta-blockers should be initiated in all eligible HFrEF patients, even when asymptomatic or when symptoms are mild 1